CORRECTED-Serono to launch study of psoriasis drug Raptiva
Posted on: Monday, 24 July 2006, 12:57 CDT
Corrects "last week" to "last year" in 7th paragraph.
ZURICH (Reuters) - Swiss pharmaceutical firm Serono said it was launching a study of its Raptiva psoriasis treatment in Europe after U.S. regulators warned recently that the drug may be linked to a risk of anemia.
Serono said in a statement on Monday that the main objective of the seven-year study involving 7,000 adult patients with moderate to severe plaque psoriasis was to gather additional long-term safety data about Raptiva.
"The study will ... provide physicians with additional clinical evidence of the long-term safety profile of Raptiva in psoriasis in clinical practice" a Serono statement quoted Franck Latrille, the company's senior executive vice president global product development as saying.
The study would also help gather data on the long-term safety profile of other treatments for psoriasis.
The study would be carried out in dermatology centers in European hospitals as well as in private dermatology clinics.
Serono has said Raptiva is successful in patients with moderate to severe plaque psoriasis, a skin condition noted for its red and scaly patches, and in patients who had undergone earlier treatments which had failed.
Genentech, which has development and marketing rights for Raptiva in the United States, and the U.S. Food and Drug Administration last year added a warning of the risk of a certain type of anemia occurring with Raptiva.
They also strengthened warnings about the risk of serious infections and decreased blood platelets that may be associated with the drug's use.
Raptiva won U.S. approval in October 2003.
Source: REUTERS
Related Articles
- SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
- Quantros Director of Patient Safety and Risk Management is Elected Co-Chair of Patient Safety Special Interest Group (PSSIG) at HL7
- Long-Term Safety Data on Lialda(TM) (Mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
- Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia
- Clinical Data Starts Long-Term Safety Study for Vilazodone
- INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
- Shire Plc - Statement Regarding the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting
- Kendle Experts Comment on Key Issues Regarding Drug Safety and Risk Management at the FDA Regulatory and Compliance Symposium at Harvard University
- New Study Confirms Long-Term Safety and Tolerability of ZOMIG(R) (Zolmitriptan) Nasal Spray for Treatment of Migraine
- Experts to Discuss Arthritis Drug Risks
 |
 |
User Comments (0)
RSS Feeds